For example, the current Spanish recommendations suggest somatic RET mutation testing in advanced/metastatic sporadic MTC, but make no mention of other targetable genetic lesions in DTC and ATC [14]. This evidence concerns the gene RET and medullary thyroid gland carcinoma.